Daewoong Co 003090.KS · KRW

Its shares trade on KRX under the ticker 003090.KS. It has been listed since 26 June 1973. In the fiscal year to 31 December 2025, it reported revenue of ₩2.07trn and net income of ₩175.06bn. At that date it held total assets of ₩3.23trn and shareholders' equity of ₩1.18trn.

Daewoong Co., Ltd. engages in the management of its subsidiaries. The company is headquartered in Seongnam, Gyeonggi-Do. The firm operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Jae Chun YoonPresident, Chief Executive Officer, Director, since 2004
• Mr. Gi Ho SongVice President, Director, since 2023
• Mr. Wu Bang JeonInternal Auditor, since 2021
• Mr. Yin Hyeok ChoiNon-Executive Independent Director
• Mr. Yeong Cheol KangNon-Executive Independent Director
• Mr. Hun Seok LeeNon-Executive Independent Director
• Seong Jae JungIR Contact Officer, since 2023

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.